Welcome to our dedicated page for Senseonics SEC filings (Ticker: SENS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Senseonics Holdings, Inc. filings document the public-company disclosures of a medical technology issuer commercializing implantable continuous glucose monitoring products for diabetes care. Its Form 8-K reports furnish operating results and business updates for Eversense CGM systems, including commercialization activity, clinical or regulatory disclosures, product integrations and financial outlook commentary.
The company’s regulatory record also covers capital-structure and financing matters, including public offerings of common stock and pre-funded warrants and amendments to debt arrangements. Proxy materials disclose board elections, executive compensation votes, auditor ratification, authorized-share proposals and equity incentive plan matters. A Form 25 filing documents the voluntary withdrawal of Senseonics common stock from listing and registration on NYSE American.
Senseonics Holdings, Inc. Chief Financial Officer reports routine tax withholding on vested stock units. On the reported date, Frederick T. Sullivan had 9,005 shares of common stock withheld at $5.82 per share to cover withholding tax obligations tied to the vesting of restricted stock units. These are not open-market sales, but shares retained by the company for tax payment. After this transaction, he directly holds 141,621 shares of Senseonics common stock.
Senseonics Holdings, Inc. director and Chief Medical Officer Francine Kaufman reported a tax-related share disposition tied to equity compensation. On this Form 4, 6,058 shares of common stock were withheld at $5.82 per share to cover withholding tax obligations upon the vesting of restricted stock units. After this withholding, Kaufman directly holds 117,890 shares of Senseonics common stock.
Senseonics Holdings Chief Operating Officer Mukul Jain reported a routine tax-related share withholding. On the vesting of restricted stock units, 13,681 shares of common stock were withheld at $5.82 per share to satisfy withholding tax obligations. Following this non-market transaction, he directly holds 246,298 shares of Senseonics common stock.
Senseonics Holdings, Inc. President and CEO Timothy T. Goodnow reported a routine tax-related share disposition. On the vesting of restricted stock units, 28,598 shares of common stock were withheld at $5.82 per share to cover withholding tax obligations. After this transaction, he directly holds 622,645 shares of Senseonics common stock.
Senseonics Holdings, Inc. reported that GC & Corp. Development Advisor Kenneth L. Horton had 7,320 shares of common stock withheld on May 15, 2026 to cover withholding tax obligations from vesting restricted stock units. After this tax-withholding disposition, he directly holds 137,114 shares of Senseonics common stock.
Senseonics Holdings director Douglas A. Roeder bought additional shares of the company’s common stock in an open-market transaction. On this trade, he purchased 22,686 shares at a price of $5.56 per share. After the transaction, he directly holds 144,635 shares of Senseonics common stock.
Senseonics Holdings, Inc. reported higher sales but wider losses for the quarter ended March 31, 2026 as it internalizes commercialization of its Eversense implantable CGM systems.
Total revenue rose to $11.7 million from $6.3 million a year earlier, driven mainly by U.S. sales now representing nearly 80% of revenue. However, operating expenses increased sharply, leading to a net loss of $32.3 million, compared with a $14.3 million loss in the prior-year quarter. Cash, cash equivalents and marketable securities were $64.3 million as of March 31, 2026. Subsequent to quarter end, the company raised an estimated $86.0 million net through an underwritten equity offering and secured access to up to $140.0 million in term loans, and management concluded that prior substantial doubt about its ability to continue as a going concern has been alleviated.
Senseonics Holdings, Inc. reported first quarter 2026 revenue of $11.7 million, up from $6.3 million a year earlier, reflecting 87% growth driven mainly by U.S. sales of the Eversense continuous glucose monitoring systems. U.S. revenue was $9.3 million, while revenue outside the U.S. was $2.4 million.
Gross profit rose to $6.9 million from $1.5 million, but higher operating spending linked to bringing Eversense commercialization in-house pushed the net loss to $32.3 million, or $0.71 per share, compared with a $14.3 million loss, or $0.40 per share, in the prior-year quarter.
Cash, cash equivalents and investments totaled $64.6 million with indebtedness of $35.2 million, after securing over $100 million in equity and debt financing. For full-year 2026, the company now expects global net revenue of $60–$64 million, representing 70%–82% growth, and gross margins of 55%–58%.
Senseonics Holdings, Inc. amended its existing term loan facility with Hercules Capital, expanding access to up to $140.0 million in senior secured term loans. The structure now includes a previously funded $35.0 million initial loan, a $10.0 million Tranche 2 loan and a $10.0 million Tranche 3A loan that the company expects to be funded at the Second Amendment closing on May 6, 2026, plus additional future tranches subject to milestones.
The loans bear interest at the greater of the prime rate plus 2.40% or 9.90% annually and mature on September 3, 2029, with an interest-only period potentially lasting until maturity if a specified 2025 milestone is met. Senseonics will pay a $100,000 facility fee, a $100,000 amendment fee, tiered prepayment penalties, and extra facility fees on later tranches.
In connection with each funded tranche, the company will issue additional stock purchase warrants exercisable for a number of common shares equal to 2.0% of the funded loan amount divided by the three-day volume-weighted average share price, adding potential future equity dilution alongside increased debt capacity.
Senseonics Holdings, Inc. amended its existing term loan facility with Hercules Capital, expanding access to up to $140.0 million in senior secured term loans. The structure now includes a previously funded $35.0 million initial loan, a $10.0 million Tranche 2 loan and a $10.0 million Tranche 3A loan that the company expects to be funded at the Second Amendment closing on May 6, 2026, plus additional future tranches subject to milestones.
The loans bear interest at the greater of the prime rate plus 2.40% or 9.90% annually and mature on September 3, 2029, with an interest-only period potentially lasting until maturity if a specified 2025 milestone is met. Senseonics will pay a $100,000 facility fee, a $100,000 amendment fee, tiered prepayment penalties, and extra facility fees on later tranches.
In connection with each funded tranche, the company will issue additional stock purchase warrants exercisable for a number of common shares equal to 2.0% of the funded loan amount divided by the three-day volume-weighted average share price, adding potential future equity dilution alongside increased debt capacity.
Senseonics Holdings, Inc. is registering 8,000,000 shares of common stock and, in lieu of common shares to certain investors, 8,000,000 pre-funded warrants to purchase common stock pursuant to this prospectus supplement.
The offering price is $5.00 per share (pre-funded warrant purchase price $4.999), with gross proceeds of approximately $79.992 million before underwriting discounts and commissions and expected net proceeds of about $74.7 million, which the company intends to use to fund the ongoing launch of Eversense 365, pipeline development, working capital and general corporate purposes.